Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Maeda

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Current Medical Research and Opinion|May 3, 2022
Characteristics and clinical outcomes of Japanese patients with venous thromboembolism receiving under-dose rivaroxaban: subanalysis of J'xactlyDaisuke Fukamachi, Yasuo Okumura, Ikuo Fukuda, et al.
Frontiers in Cardiovascular Medicine|February 27, 2023
Relationship between baseline D-dimer and prognosis in Japanese patients with venous thromboembolism: Insights from the J'xactly studyShohei Migita, Yasuo Okumura, Ikuo Fukuda, et al.
Thrombosis Journal|February 27, 2015
Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE programNorikazu Yamada, Atsushi Hirayama, Hideaki Maeda, et al.
The Review of Scientific Instruments|November 7, 2012
Towards a beyond 1 GHz solid-state nuclear magnetic resonance: external lock operation in an external current mode for a 500 MHz nuclear magnetic resonanceMasato Takahashi, Yusuke Ebisawa, Konosuke Tennmei, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|May 28, 2023
Safety Profile and Effectiveness of Rivaroxaban for Patients With Venous Thromboembolism in Japan　- Results From Post-Marketing Surveillance (XASSENT)Ikuo Fukuda, Atsushi Hirayama, Kazuo Kawasugi, et al.
International Heart Journal|February 21, 2022
Clinical Implication of the Right Ventricular/Left Ventricular Diameter Ratio in Patients with Pulmonary ThromboembolismMasatsugu Miyagawa, Yasuo Okumura, Daisuke Fukamachi, et al.
Thrombosis Journal|May 26, 2016
Erratum to: 'Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program'Norikazu Yamada, Atsushi Hirayama, Hideaki Maeda, et al.
Journal of Natural Products|November 4, 2017
Houttuynoid M, an Anti-HSV Active Houttuynoid from Houttuynia cordata Featuring a Bis-houttuynin Chain Tethered to a Flavonoid CoreJiao-Jiao Li, Guo-Dong Chen, Hong-Xia Fan, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|December 8, 2021
Design and Baseline Data for a Prospective Observational Study of Rivaroxaban in Patients with Venous Thromboembolism in Japan (XASSENT)Ikuo Fukuda, Atsushi Hirayama, Kazuo Kawasugi, et al.
Protein and Peptide Letters|February 23, 2005
Efficient immobilization of enzymes on microchannel surface through His-tag and application for microreactorMasaya Miyazaki, Jun Kaneno, Susumu Yamaori, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Current Medical Research and Opinion|May 3, 2022
Characteristics and clinical outcomes of Japanese patients with venous thromboembolism receiving under-dose rivaroxaban: subanalysis of J'xactlyDaisuke Fukamachi, Yasuo Okumura, Ikuo Fukuda, et al.
Frontiers in Cardiovascular Medicine|February 27, 2023
Relationship between baseline D-dimer and prognosis in Japanese patients with venous thromboembolism: Insights from the J'xactly studyShohei Migita, Yasuo Okumura, Ikuo Fukuda, et al.
Thrombosis Journal|February 27, 2015
Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE programNorikazu Yamada, Atsushi Hirayama, Hideaki Maeda, et al.
The Review of Scientific Instruments|November 7, 2012
Towards a beyond 1 GHz solid-state nuclear magnetic resonance: external lock operation in an external current mode for a 500 MHz nuclear magnetic resonanceMasato Takahashi, Yusuke Ebisawa, Konosuke Tennmei, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|May 28, 2023
Safety Profile and Effectiveness of Rivaroxaban for Patients With Venous Thromboembolism in Japan　- Results From Post-Marketing Surveillance (XASSENT)Ikuo Fukuda, Atsushi Hirayama, Kazuo Kawasugi, et al.
International Heart Journal|February 21, 2022
Clinical Implication of the Right Ventricular/Left Ventricular Diameter Ratio in Patients with Pulmonary ThromboembolismMasatsugu Miyagawa, Yasuo Okumura, Daisuke Fukamachi, et al.
Thrombosis Journal|May 26, 2016
Erratum to: 'Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program'Norikazu Yamada, Atsushi Hirayama, Hideaki Maeda, et al.
Journal of Natural Products|November 4, 2017
Houttuynoid M, an Anti-HSV Active Houttuynoid from Houttuynia cordata Featuring a Bis-houttuynin Chain Tethered to a Flavonoid CoreJiao-Jiao Li, Guo-Dong Chen, Hong-Xia Fan, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|December 8, 2021
Design and Baseline Data for a Prospective Observational Study of Rivaroxaban in Patients with Venous Thromboembolism in Japan (XASSENT)Ikuo Fukuda, Atsushi Hirayama, Kazuo Kawasugi, et al.
Protein and Peptide Letters|February 23, 2005
Efficient immobilization of enzymes on microchannel surface through His-tag and application for microreactorMasaya Miyazaki, Jun Kaneno, Susumu Yamaori, et al.
Pageof 9